Does the media prefer NAUT or HYFT?

In the previous week, Nautilus Biotechnology had 5 more articles in the media than MindWalk. MarketBeat recorded 8 mentions for Nautilus Biotechnology and 3 mentions for MindWalk. Nautilus Biotechnology's average media sentiment score of 0.70 beat MindWalk's score of 0.19 indicating that Nautilus Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is QTRX or HYFT more profitable?

Quanterix has a net margin of -80.25% compared to MindWalk's net margin of -105.11%. Quanterix's return on equity of -26.09% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -80.25% -26.09% -19.03% MindWalk -105.11% -133.26% -77.78%

Is CDXS or HYFT more profitable?

Codexis has a net margin of -39.55% compared to MindWalk's net margin of -105.11%. Codexis' return on equity of -74.36% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% MindWalk -105.11% -133.26% -77.78%

Does the media prefer CDXS or HYFT?

In the previous week, Codexis and Codexis both had 3 articles in the media. MindWalk's average media sentiment score of 0.19 beat Codexis' score of 0.00 indicating that MindWalk is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, SEER or HYFT?

MindWalk has lower revenue, but higher earnings than Seer. MindWalk is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seer $16.58M 7.51 -$73.60M -$1.22 N/A MindWalk $11.24M 5.57 -$10.11M -$0.26 N/A

Is SEER or HYFT more profitable?

MindWalk has a net margin of -105.11% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Seer -478.05% -27.23% -23.99% MindWalk -105.11% -133.26% -77.78%

Does the media favor SEER or HYFT?

In the previous week, MindWalk had 2 more articles in the media than Seer. MarketBeat recorded 3 mentions for MindWalk and 1 mentions for Seer. Seer's average media sentiment score of 0.87 beat MindWalk's score of 0.19 indicating that Seer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seer 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MXCT or HYFT more profitable?

MindWalk has a net margin of -105.11% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -114.77% -18.92% -16.14% MindWalk -105.11% -133.26% -77.78%

Does the media refer more to MXCT or HYFT?

In the previous week, MindWalk had 2 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for MindWalk and 1 mentions for MaxCyte. MindWalk's average media sentiment score of 0.19 beat MaxCyte's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MindWalk (HYFT) Competitors

$1.49 +0.15 (+11.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.49 0.00 (-0.07%)

As of 07:58 PM Eastern

Compare

HYFT vs. NAUT, QTRX, CDXS, SEER, and MXCT

Should you buy MindWalk stock or one of its competitors? MindWalk's main competitors and comparable companies include Nautilus Biotechnology (NAUT), Quanterix (QTRX), Codexis (CDXS), Seer (SEER), and MaxCyte (MXCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MindWalk compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Nautilus Biotechnology has a net margin of 0.00% compared to MindWalk's net margin of -105.11%. Nautilus Biotechnology's return on equity of -37.58% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
MindWalk	-105.11%	-133.26%	-77.78%

Nautilus Biotechnology has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Nautilus Biotechnology presently has a consensus price target of $3.83, suggesting a potential upside of 95.58%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 273.13%. Given MindWalk's higher probable upside, analysts clearly believe MindWalk is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

MindWalk has higher revenue and earnings than Nautilus Biotechnology. MindWalk is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
MindWalk	$11.24M	5.57	-$10.11M	-$0.26	N/A

In the previous week, Nautilus Biotechnology had 5 more articles in the media than MindWalk. MarketBeat recorded 8 mentions for Nautilus Biotechnology and 3 mentions for MindWalk. Nautilus Biotechnology's average media sentiment score of 0.70 beat MindWalk's score of 0.19 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nautilus Biotechnology beats MindWalk on 8 of the 13 factors compared between the two stocks.

How does MindWalk compare to Quanterix?

Quanterix (NASDAQ:QTRX) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Quanterix currently has a consensus target price of $3.00, suggesting a potential downside of 17.58%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 273.13%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, MindWalk had 3 more articles in the media than Quanterix. MarketBeat recorded 3 mentions for MindWalk and 0 mentions for Quanterix. MindWalk's average media sentiment score of 0.19 beat Quanterix's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company	Overall Sentiment
Quanterix	Neutral
MindWalk	Neutral

Quanterix has a net margin of -80.25% compared to MindWalk's net margin of -105.11%. Quanterix's return on equity of -26.09% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
MindWalk	-105.11%	-133.26%	-77.78%

86.5% of Quanterix shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quanterix has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

MindWalk has lower revenue, but higher earnings than Quanterix. MindWalk is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.24	-$107.15M	-$2.63	N/A
MindWalk	$11.24M	5.57	-$10.11M	-$0.26	N/A

Summary

MindWalk beats Quanterix on 10 of the 17 factors compared between the two stocks.

How does MindWalk compare to Codexis?

Codexis (NASDAQ:CDXS) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

In the previous week, Codexis and Codexis both had 3 articles in the media. MindWalk's average media sentiment score of 0.19 beat Codexis' score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.5% of Codexis shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MindWalk has lower revenue, but higher earnings than Codexis. MindWalk is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.12	-$43.97M	-$0.34	N/A
MindWalk	$11.24M	5.57	-$10.11M	-$0.26	N/A

Codexis has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Codexis presently has a consensus target price of $6.50, indicating a potential upside of 377.94%. MindWalk has a consensus target price of $5.00, indicating a potential upside of 273.13%. Given Codexis' higher probable upside, equities research analysts plainly believe Codexis is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Codexis has a net margin of -39.55% compared to MindWalk's net margin of -105.11%. Codexis' return on equity of -74.36% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
MindWalk	-105.11%	-133.26%	-77.78%

Summary

Codexis beats MindWalk on 8 of the 15 factors compared between the two stocks.

How does MindWalk compare to Seer?

Seer (NASDAQ:SEER) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Seer has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

MindWalk has a net margin of -105.11% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
MindWalk	-105.11%	-133.26%	-77.78%

MindWalk has lower revenue, but higher earnings than Seer. MindWalk is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	7.51	-$73.60M	-$1.22	N/A
MindWalk	$11.24M	5.57	-$10.11M	-$0.26	N/A

Seer presently has a consensus price target of $4.00, suggesting a potential upside of 77.78%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 273.13%. Given MindWalk's higher possible upside, analysts clearly believe MindWalk is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

75.2% of Seer shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, MindWalk had 2 more articles in the media than Seer. MarketBeat recorded 3 mentions for MindWalk and 1 mentions for Seer. Seer's average media sentiment score of 0.87 beat MindWalk's score of 0.19 indicating that Seer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Seer beats MindWalk on 11 of the 17 factors compared between the two stocks.

How does MindWalk compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

MaxCyte has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

MindWalk has lower revenue, but higher earnings than MaxCyte. MindWalk is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.34	-$44.63M	-$0.33	N/A
MindWalk	$11.24M	5.57	-$10.11M	-$0.26	N/A

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, MindWalk had 2 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for MindWalk and 1 mentions for MaxCyte. MindWalk's average media sentiment score of 0.19 beat MaxCyte's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MaxCyte presently has a consensus target price of $5.00, suggesting a potential upside of 367.29%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 273.13%. Given MaxCyte's higher possible upside, equities analysts plainly believe MaxCyte is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

MindWalk has a net margin of -105.11% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
MindWalk	-105.11%	-133.26%	-77.78%

Summary

MindWalk beats MaxCyte on 10 of the 17 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69.60M	$11.02B	$7.17B	$13.38B
Dividend Yield	N/A	1.44%	2.53%	17.32%
P/E Ratio	-5.73	32.96	274.64	26.20
Price / Sales	6.19	108.72	608.57	90.53
Price / Cash	N/A	27.32	27.22	34.70
Price / Book	8.28	7.24	11.26	6.40
Net Income	-$10.11M	$57.48B	$3.49B	$381.07M
7 Day Performance	11.19%	3.88%	-1.68%	-0.66%
1 Month Performance	12.88%	10.61%	-5.97%	-4.51%
1 Year Performance	N/A	36.19%	8.11%	1.82%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	2.8122 of 5 stars	$1.49 +11.2%	$5.00 +235.6%	N/A	$62.59M	$11.24M	N/A	77	High Trading Volume
NAUT Nautilus Biotechnology	2.9764 of 5 stars	$1.79 +13.7%	$3.83 +114.8%	+122.1%	$225.87M	N/A	N/A	130	News Coverage Options Volume Gap Up High Trading Volume
QTRX Quanterix	0.9349 of 5 stars	$3.58 +4.8%	$3.00 -16.1%	-40.1%	$169.11M	$138.90M	N/A	450
CDXS Codexis	1.8411 of 5 stars	$1.36 flat	$6.50 +377.9%	-46.5%	$148.93M	$70.39M	N/A	146
SEER Seer	3.657 of 5 stars	$2.24 +1.6%	$4.00 +79.0%	-1.3%	$123.75M	$16.58M	N/A	124	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors

HYFT vs. NAUT, QTRX, CDXS, SEER, and MXCT

How does MindWalk compare to Nautilus Biotechnology?

Summary

How does MindWalk compare to Quanterix?

Summary

How does MindWalk compare to Codexis?

Summary

How does MindWalk compare to Seer?

Summary

How does MindWalk compare to MaxCyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MindWalk (HYFT) Competitors

HYFT vs. NAUT, QTRX, CDXS, SEER, and MXCT

How does MindWalk compare to Nautilus Biotechnology?

Is NAUT or HYFT more profitable?

Which has more risk and volatility, NAUT or HYFT?

Do analysts recommend NAUT or HYFT?

Which has higher earnings and valuation, NAUT or HYFT?

Does the media prefer NAUT or HYFT?

Do institutionals and insiders have more ownership in NAUT or HYFT?

Summary

How does MindWalk compare to Quanterix?

Do analysts rate QTRX or HYFT?

Does the media favor QTRX or HYFT?

Is QTRX or HYFT more profitable?

Do insiders & institutionals have more ownership in QTRX or HYFT?

Which has more risk & volatility, QTRX or HYFT?

Which has higher earnings & valuation, QTRX or HYFT?

Summary

How does MindWalk compare to Codexis?

Does the media prefer CDXS or HYFT?

Do institutionals & insiders believe in CDXS or HYFT?

Which has better earnings and valuation, CDXS or HYFT?

Which has more volatility and risk, CDXS or HYFT?

Do analysts recommend CDXS or HYFT?

Is CDXS or HYFT more profitable?

Summary

How does MindWalk compare to Seer?

Which has more risk & volatility, SEER or HYFT?

Is SEER or HYFT more profitable?

Which has higher earnings & valuation, SEER or HYFT?

Do analysts rate SEER or HYFT?

Do insiders & institutionals hold more shares of SEER or HYFT?

Does the media favor SEER or HYFT?

Summary

How does MindWalk compare to MaxCyte?

Which has more risk and volatility, MXCT or HYFT?

Which has stronger earnings and valuation, MXCT or HYFT?

Do institutionals and insiders hold more shares of MXCT or HYFT?

Does the media refer more to MXCT or HYFT?

Do analysts rate MXCT or HYFT?

Is MXCT or HYFT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools